XBiotech

XBiotech XBiotech is a fully integrated biopharmaceutical that uses proprietary technology to create True Human™ monoclonal antibody medicines.

True Human™ antibodies harness natural immunity and allow us to share the best of natural immunity for all. At XBiotech we are rethinking the way medicines are discovered and commercialized—from pioneering ways to create safer drugs that harness our natural immunity to disease, to developing technology that enables rapid transition from discovery to large-scale manufacturing.

From Lab to Cover: XBiotech Scientists Earn Cover Recognition in the Texas Journal of Microscopy
05/01/2026

From Lab to Cover: XBiotech Scientists Earn Cover Recognition in the Texas Journal of Microscopy

XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.

XBiotech Awarded Three U.S. Patents Protecting Next-Generation True Human™ Antibodies Targeting Interleukin-1 Alpha
03/06/2026

XBiotech Awarded Three U.S. Patents Protecting Next-Generation True Human™ Antibodies Targeting Interleukin-1 Alpha

XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.

XBiotech We Believe.
08/23/2024

XBiotech We Believe.

XBiotech’s technologies provide us with the unique ability to develop drug candidates for viral or bacterial infectious diseases. Our core discovery technolo...

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pa...
06/18/2024

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind,

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
01/04/2024

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
11/14/2023

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

(Phase II Multicenter Study is Proceeding Well with High Anticipation) AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
09/26/2023

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical

Address

5217 Winnebago Lane
Austin, TX
78744

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when XBiotech posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category